Hutruo (bermekimab IV)

News alerts, weekly reports and conference planners

Company:

J&J

Drug class:

IL-1α inhibitor

Related drugs:

‹

›

almost5years

[VIRTUAL] A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX). (ASCO 2020)

We report results of a single site phase 1 trial for an IL-1α antagonist (bermekimab) in combination with nanoliposomal irinotecan (Nal-Iri) and 5-fluorouracil (5FU)/folinic acid (FA) in patients with advanced pancreatic adenocarcinoma and cachexia who have failed gemcitabine-based chemotherapy... Bermekimab, nano-liposomal irinotecan and 5-fluorouracil in refractory pancreatic cancer patients with cachexia was well-tolerated with promising efficacy and improvements in patient performance. Research Funding: Ipsen

almost 5 years ago

Clinical • P1 data • Combination therapy

IL1A (Interleukin 1, alpha)

gemcitabine • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical • Hutruo (bermekimab IV)

5years

A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX). (ASCO-GI 2020)

The present study aims to establish the safety of an IL-1α antagonist (Bermekimab) in combination with nanoliposomal irinotecan (Nal-Iri) and 5-fluorouracil (5FU)/folinic acid (FA) in patients with advanced pancreatic adenocarcinoma and cachexia who have failed gemcitabine-based chemotherapy. Clinical trial information: NCT03207724. Research Funding: Ipsen and XBiotech, Inc

5 years ago

Clinical • P1 data • Combination therapy

IL1A (Interleukin 1, alpha)

gemcitabine • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • Hutruo (bermekimab IV)